This review summarizes the current state of anticoagulation therapy in patients with atrial fibrillation, highlighting clinical scenarios and regional differences between western and eastern populations.
Answers are grounded in this paper and cite their sources.
Regional AF anticoagulation differences merit clinical consideration; leaves open optimal East-West strategies for prospective trials.
Atrial fibrillation (AF) increases the risk of stroke. New anticoagulation agents have recently provided alternative and promising approaches. This paper reviews the current state of anticoagulation therapy in AF patients, focusing on various clinical scenarios and on comparisons, where possible, between western and eastern populations.
No takes yet. Share an insight, caveat, or question.
Shu Zhang (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: